Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Cytokinetics, Incorporated
CYTK
NASDAQ·Healthcare·Biotechnology·Mkt cap $10.6B
$86.54
▲ +1.50%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$32.89 - $88.31
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 148.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary muscle biology platform and deep cardiac/skeletal muscle physiology expertise
- Multiple late-stage clinical programs with first-in-class and best-in-class potential
- Strategic partnership with Astellas Pharma providing development and commercialization support
- Novel mechanism of action targeting muscle contractility with limited competitive landscape
Bear Case
2 risks
- Low volatility (beta 0.4).
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Moderate growth ahead
Strong revenue growth (377% YoY)
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Hot
+27.8% over 3m
Quality
Excellent
High-growth business (451% revenue growth, 90% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying CYTK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 5, 2026
Reported EPS of -$1.67 vs -$1.67 consensus (0.0% surprise). Revenue of $19.4M vs $8.5M expected (+127.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
0.0%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
+912%
+89%
+26715%
+318%
+5%
+1126%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$249.0K
$463.0K
$16.9M
$1.6M
$66.8M
$1.9M
$17.8M
$19.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
-1064.5%
Wall Street consensus
14 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$108.00
▲ +24.8% vs $86.54
Latest: UBS · $115.00 · Jun 29, 2026
6 analysts covering